Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk

Figures & data

Table 1 Low-density lipoprotein (LDL) reduction/ATP III goal achievement in comparison study (STELLAR trial), meta-analysis and in a real life (REALITY) study.

	Pravastatin	Lovastatin	Fluvastatin	Simvastatin	Atorvastatin	Rosuvastatin
LDL reduction on 40 mg/day (meta-analysis)^Citation15	29%	37%	27%	37%	49%	53%
LDL reduction (%) STELLAR^Citation8 40 mg/day	29.7%^Table Footnote*	NA	NA	38.8%*	47.8%*	55%
80 mg/day	NA	NA	NA	45.8%*	51.1%*	NA
Attainment of ATP III goals (STELLAR) (% of patients)^Citation8 on maximal dose	54%^Table Footnote*	NA	NA	82%	85%	89%
Real life ATP III goal attainment REALITY study (% of patients)^Citation57	10 mg 35.9%	20.0%	NA	52.5%	56.4%	NA
	20 mg 37.9%	15.9%	33.0%	45.5%	40.0 %
	40 mg 38.9%	5.6%	34.3%	29.9%	27.2%
	80 mg NA	NA	28.6%	11.4%	6.7%

* Statistically significant compared to the rosuvastatin 40 mg PPO daily; p < 0.002 is statistically significant.⁸

LawMRWaldNJRudnickaARQuantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ2003326142312829554

 PubMed Web of Science ®Google Scholar

JonesPHDavidsonMHSteinEAComparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)Am J Cardiol20039215216012860216

 PubMed Web of Science ®Google Scholar

Van GanseELaforestLAlemaoEDaviesGGutkinSYinDLipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) studyCurr Med Res Opin2005211389139916197657

 PubMed Web of Science ®Google Scholar